Risk factors for gastrointestinal and hepatic adverse reactions in rheumatoid arthritis patients on biologic and conventional dmards

HIGHLIGHTS

• What: The aim of this study is to determine risk factors for gastrointestinal and hepatic ADRs in RA patients receiving biologic agents in combination with conventional DMARDs. The authors seek to enhance personalized treatment strategies by identification of patient characteristics and treatment related factors contributing to ADRs and to improve patient Page 69 of 76 care by decreasing the treatment safety profile of RA therapies .
• Who: Arslan Shuja from the of Medicine and Dentistry (UCMD), Lahore, Pakistan have published the research work: DEVELOPMENTAL MEDICO-LIFE-SCIENCES, in the Journal: (JOURNAL)
• How: The authors . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.